Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc. V.KNE

Alternate Symbol(s):  KNBIF

Healthcare Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.


TSXV:KNE - Post by User

Kane Biotech Inc. > New Press Release - Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(102)
•••
Comment by francoisl13on Mar 20, 2024 10:54am
45 Views
Post# 35942771

RE:New Press Release - Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health

RE:New Press Release - Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal HealthAs expected (hoped...), the STEM deal is very likely going to be signed before the end of March. It is pretty obvious, when considerng the amount of money paid upfront (and deductible from the STEM sales value) that this is moving forward.
So far KNE got 1.5M in 'upfront payments'....from past discussions with various people, expectations for the sales of the STEM division were ranging from 6 to 11M...I'm eager to see what Mr. Renaud met when he said that they were pleased that the offer received was reflecting STEM's full value in the December 20th press release.
GLTA
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities